Endurance Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Endurance Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$0	Hold	400	–	–	﹤0.01%	647
2023 Q1	$1K	Hold	400	–	–	﹤0.01%	624
2022 Q4	$1K	Hold	400	–	–	﹤0.01%	612
2022 Q3	$2K	Hold	400	–	–	﹤0.01%	563
2022 Q2	$1K	Hold	400	–	–	﹤0.01%	604
2022 Q1	$2K	Hold	400	–	–	﹤0.01%	608
2021 Q4	$4K	Hold	400	–	–	﹤0.01%	552
2021 Q3	$4K	Hold	400	–	–	﹤0.01%	561
2021 Q2	$6K	Hold	400	–	–	﹤0.01%	555
2021 Q1	$6K	Hold	400	–	–	﹤0.01%	565
2020 Q4	$8K	Hold	400	–	–	﹤0.01%	510
2020 Q3	$6K	Hold	400	–	–	﹤0.01%	521
2020 Q2	$6K	Hold	400	–	–	﹤0.01%	503
2020 Q1	$5K	Buy	+400	New	+$7.52K	﹤0.01%	467

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Endurance Wealth Management's HRTX Position: Q2 2023 in Review

Endurance Wealth Management held its Heron Therapeutics (HRTX) position steady in Q2 2023 at 400 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #647.

Endurance Wealth Management first reported a position in HRTX in Q1 2020 and has held it in 14 quarters since. The position peaked at $8K in Q4 2020. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

Endurance Wealth Management held 400 shares of Heron Therapeutics worth $0 as of Q2 2023.
Endurance Wealth Management left its Heron Therapeutics share count unchanged in Q2 2023.
Heron Therapeutics made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #647 holding.
Endurance Wealth Management first reported a position in Heron Therapeutics in Q1 2020 and has held it in 14 quarters since.
Endurance Wealth Management's Heron Therapeutics position peaked at $8K in Q4 2020.
149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.